Status:
UNKNOWN
Effect of Intraperitoneal Ropivacaine on Visceral Pain After Laparoscopic Gastrectomy
Lead Sponsor:
SanQing Jin
Conditions:
Laparoscopic Gastrectomy
Ropivacaine
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
Visceral pain is obvious and lasts for a long time in patients after laparoscopic gastrectomy.Relieving the visceral pain is of great significance for patients' postoperative emotional experience, fun...
Detailed Description
Postoperative pain is a common adverse reaction after laparoscopic gastrectomy. Insufficient analgesia can cause severe stress response,affect the recovery of postoperative gastrointestinal function, ...
Eligibility Criteria
Inclusion
- Age 18-65 years old
- The American Society of Anesthesiologists(ASA) grade is I or II, and the heart function grade is 1-2;
- Elective laparoscopic gastrectomy under general anesthesia
Exclusion
- Patients have severe heart, lung, liver, and kidney diseases (heart function grade\>3 / respiratory failure / liver failure / renal failure)
- BMI\<18kg/m2 or \>30kg/m2
- Patients with chronic pain other than stomach pain and taking analgesics for a long time
- Patients with history of allergy to local anesthetics
- Patients with high risk of reflux and aspiration such as digestive obstruction
- Patients who refuse to participate or don't sign or refuse to sign the informed consent form
- Patients who are unable to communicate effectively
- Patients participate in other clinical trials
Key Trial Info
Start Date :
November 25 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 7 2024
Estimated Enrollment :
72 Patients enrolled
Trial Details
Trial ID
NCT06145945
Start Date
November 25 2023
End Date
July 7 2024
Last Update
November 28 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
SanQing Jin
Guangzhou, Guangdong, China